MacroGenics' Margenza shows no advantage over Herceptin

8 September 2021

US oncology specialist MacroGenics (Nasdaq: MGNX) was trading 4% lower at lunchtime in the USA on Wednesday, after presenting the final overall survival (OS) results of the SOPHIA Phase III in metastatic HER2-positive breast cancer.

The results relate to MacroGenics’ Margenza, which was approved last year by the US Food and Drug Administration (FDA) in combination with chemotherapy for the treatment of adults with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

"We continue to believe Margenza may be the right choice for certain patients"The basis for this full approval was the progression-free survival (PFS) results in the SOPHIA study, which compared Margenza plus chemotherapy to trastuzumab, a drug marketed by Roche (ROG: SIX) under the name Herceptin, alongside chemotherapy in patients with metastatic HER2-positive breast cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK